Patents Assigned to Synta Pharmaceuticals Corp.
  • COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH RADIOTHERAPY
    Publication number: 20140051664
    Abstract: Methods for treating cancer in a subject, comprising administering to the subject an effective amount of a compound represented by the following structural formula a tautomer, or a pharmaceutically acceptable salt thereof in combination with radiotherapy. The variables depicted in the structural formula are defined herein.
    Type: Application
    Filed: February 22, 2012
    Publication date: February 20, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Kevin P. Foley, David Proia
  • PROSTATE CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS
    Publication number: 20140051665
    Abstract: Method for treating a subject with prostate cancer, comprising administering to the an effective amount of a compound represented by the following structural formula: a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.
    Type: Application
    Filed: February 23, 2012
    Publication date: February 20, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: David Proia, Suqin He
  • HSP90 INHIBITORY COMPOUNDS IN TREATING JAK/STAT SIGNALING-MEDIATED CANCERS
    Publication number: 20140045908
    Abstract: Methods for treating a subject with cancer mediated through dysregulated, aberrant, or defective JAK/STAT signaling, are provided, comprising determining the level of the JAK/STAT signaling in a sample derived from a subject in need of treatment, wherein the presence of dysregulated, aberrant, or defective JAK/STAT signaling is indicated, administering to the subject an effective amount of a triazolone compound as described herein.
    Type: Application
    Filed: February 24, 2012
    Publication date: February 13, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Ronald K. Blackman, Kevin P. Foley, David Proia
  • COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES
    Publication number: 20140045861
    Abstract: The invention relates to certain compounds according to Formula (I): or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders and immune disorders.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 13, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Jun Jiang, Junyi Zhang, Shoujun Chen, Lijun Sun
  • Method for treating proliferative disorders associated with mutations in c-Met
    Patent number: 8648104
    Abstract: The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating c-Met associated cancers, in a subject in need thereof.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: February 11, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Zhenjian Du, Kevin Foley
  • Hydrazonamide compounds that modulate Hsp90 activity
    Patent number: 8648071
    Abstract: The present invention relates to substituted hydrazonamide compounds. The invention further relates to methods of inhibiting the activity of Hs?90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted hydrazonamide compound of the invention, or a pharmaceutical composition comprising such a compound.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: February 11, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Joseph Burlison, Dinesh U. Chimmanamada, Weiwen Ying, Shijie Zhang, David James
  • COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES
    Publication number: 20140039009
    Abstract: The invention relates to compounds of structural formulas (I), (VII) and (XI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, Y, Z, L, R1, R2, R3, R18 and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 6, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Lijun Sun, Shoujun Chen, Zhiqiang Xia, Jun Jiang, Yu Xie, Junyi Zhang
  • Polymorphs of N-malonyl-bis(N?-methyl-N?-thiobenzoylhydrazide)
    Patent number: 8637704
    Abstract: At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: January 28, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Elena Kostik, Lijun Sun, Joanna Dziewiszek, Jun Y. Choi
  • Process for preparing bis(thiohydrazide amides)
    Patent number: 8633323
    Abstract: Disclosed herein are methods of preparing a bis(thio-hydrazide amides) compounds of the following structural formula: wherein R1, R2, R3, R4, R5, R6 and R13 are defined herein.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: January 21, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Jun Jiang, Lijun Sun, Keizo Koya
  • Imidazole compounds that modulate HSP90 activity
    Patent number: 8629285
    Abstract: Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.
    Type: Grant
    Filed: August 10, 2006
    Date of Patent: January 14, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Weiwen Ying, Zhenjian Du, Kevin Foley
  • Bis(thio-hydrazide amide) formulation
    Patent number: 8623921
    Abstract: Disclosed herein are compositions comprising a compound represented by structural formula (I): 2 g of which is reconstitutable in 10 mL of a water in less than 10 minutes, and methods for preparing these compositions. Also disclosed are compositions comprising a compound represented by structural formula (I) and a pharmaceutically acceptable excipient, wherein the molar ratio of said compound to said excipient is from 1:20 to 1:1, and methods for preparing these compositions.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: January 7, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Walter J. Lunsmann, Ninad Deshpanday
  • Substituted biaryl compounds for inflammation and immune-related uses
    Patent number: 8623871
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein A, Y, L, R1, W1 and W2 are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: January 7, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Lijun Sun, Jun Jiang, Yu Xie
  • COMBINATION BREAST CANCER THERAPY WITH HSP90 INHIBITORY COMPOUNDS
    Publication number: 20140005145
    Abstract: Methods for treating breast cancer, comprising administering to the subject an effective amount of a selective estrogen receptor modulator and an effective amount of a compound represented by the following structural formula: (I) (Ia) a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.
    Type: Application
    Filed: December 7, 2011
    Publication date: January 2, 2014
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventor: David Proia
  • Oral formulations of bis(thiohydrazide amides)
    Patent number: 8618170
    Abstract: Disclosed herein are oral formulations of bis(thio-hydrazide amides) compounds of the following structural formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R7, R8, Z, and Y are defined herein.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: December 31, 2013
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Noriaki Tatsuta, Takayo Inoue, Keizo Koya
  • TRIAZINONE AND DIAZINONE DERIVATIVES USEFUL AS HSP90 INHIBITORS
    Publication number: 20130345219
    Abstract: The present invention relates to compounds according to formulae (IA) to (ID) and compositions that inhibit the activity of Hsp90. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a compound of the invention, or a composition comprising such a compound.
    Type: Application
    Filed: August 28, 2013
    Publication date: December 26, 2013
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Chi-Wan Lee, Teresa Prezewloka, Weiwen Ying, Minghu Song, Zhenjian Du, Kevin Foley, Dan Zhou, Shuzhen Qin
  • Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
    Patent number: 8614321
    Abstract: The invention relates to compounds of structural formula (I) or (III): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein ring A, X1, X2, X3, X5, R1, R4, Y, Z, L, m and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: December 24, 2013
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Jun Jiang, Junyi Zhang, Yu Xie
  • METHOD FOR TREATING INFECTIONS
    Publication number: 20130338155
    Abstract: The present invention relates to compounds that inhibit the activity of Hsp90 and methods of using these compounds for treating or preventing infection.
    Type: Application
    Filed: June 4, 2013
    Publication date: December 19, 2013
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventor: Weiwen Ying
  • COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS
    Publication number: 20130338162
    Abstract: Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 29, 2013
    Publication date: December 19, 2013
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Lijun Sun, Keizo Koya, Shoujun Chen, Zachary Demko, Zhi-Qiang Xia
  • Compounds for treating proliferative disorders
    Patent number: 8609720
    Abstract: Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: December 17, 2013
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Keizo Koya, Zachary Demko, Lijun Sun
  • COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH PROTEASOME INHIBITORS
    Publication number: 20130331357
    Abstract: A composition comprising a proteasome inhibitor, and an Hsp90 inhibitor according to the following formulae (I) or (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder such as cancer in a subject in need thereof, using pharmaceutical combinations described herein.
    Type: Application
    Filed: January 10, 2012
    Publication date: December 12, 2013
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: David Proia, Julie Friedland